FGFR3-Altered Urothelial Carcinoma: When to Use Erdafitinib
His tumor carries the one molecular alteration with a targeted drug built for it — the actual complication is that the monitoring erdafitinib requires runs headlong into an eye disease he already has.
V.N., a 64-year-old man, has been legally blind in his left eye since a retinal detachment a decade ago and manages proliferative diabetic retinopathy in his remaining right eye with ongoing anti-VEGF injections and laser photocoagulation, care he attends without fail because, in his own words, that eye is "the only one doing any work." His metastatic urothelial carcinoma progressed after first-line enfortumab vedotin plus pembrolizumab, and tumor sequencing at progression identified an FGFR3 activating mutation — the molecular alteration erdafitinib was specifically developed to target, and the one situation in this disease where a genuinely targeted, mutation-matched therapy exists rather than a broader chemotherapy or immunotherapy option.
THOR established erdafitinib's efficacy specifically in FGFR-altered urothelial carcinoma progressing after prior therapy, including after checkpoint inhibition, making him a genuine eligibility match by treatment history and molecular profile alike. But erdafitinib's most distinctive toxicity is central serous retinopathy, a fluid accumulation under the retina requiring baseline and serial ophthalmologic monitoring with optical coherence tomography throughout treatment — monitoring built around detecting a new finding against a presumed-normal baseline retina, a premise his own retinal anatomy, already altered by longstanding diabetic disease and a prior detachment, does not meet. Distinguishing a genuine drug-related retinopathy from an exacerbation of his existing disease, in his single functioning eye, is a monitoring problem the trial's own baseline population was not built to anticipate.
His retinal specialist's own baseline OCT imaging, obtained specifically for his diabetic retinopathy management, already documents the exact contours of his existing retinal changes in more detail than a single new-patient scan obtained solely for erdafitinib monitoring would capture — an advantage the team discussed directly, since a specialist already tracking his baseline month to month is better positioned to flag a genuine deviation than a monitoring protocol reading his retina for the first time. Erdafitinib's other major toxicity, hyperphosphatemia, requires its own separate laboratory surveillance and carries no interaction with his ocular history at all.
A targeted therapy match complicated by a targeted monitoring problem
His tumor has an FGFR3 activating mutation, and he's progressed after checkpoint-inhibitor-containing therapy — that's exactly the population THOR showed erdafitinib benefits. This is the one point in his disease where we have a real, mutation-matched targeted option rather than a broader chemotherapy choice. I don't want to pass on that lightly.
The retinopathy monitoring built into erdafitinib's protocol assumes a normal baseline retina to compare against. He doesn't have one — he has longstanding proliferative diabetic retinopathy and a prior detachment in his only seeing eye. Standard OCT surveillance may not reliably tell us whether a new finding is drug effect or his known disease progressing on its own trajectory, and a missed detection in his single functioning eye is a much higher-stakes error than the same miss would be in someone with two healthy eyes.
A monitoring protocol validated against a normal baseline doesn't automatically generalize to a patient whose baseline looks nothing like the one it was designed for.
I don't think this has to be a straight yes-or-no on the drug. His retinal specialist already has detailed baseline imaging and knows exactly how his disease progresses on its own. If we bring that specialist directly into an individualized monitoring plan rather than relying on the standard protocol, we may be able to distinguish a genuinely new drug effect from his known pattern — and give him access to the therapy his tumor is actually built to respond to.
Agreed: erdafitinib started, with his existing retinal specialist directly incorporated into an individualized monitoring plan rather than relying on the standard OCT surveillance protocol alone.
Not agreed, and left as a genuinely open question depending on early monitoring results:
Erdafitinib continues on schedule, with the individualized monitoring plan treated as a durable, working solution.
The ophthalmologist would recommend stopping erdafitinib preemptively in his single functioning eye, even without certainty the finding is drug-related.